Literature DB >> 22487065

Systematic review of actual 10-year survival following resection for hepatocellular carcinoma.

Annelise M Gluer1, Nicholas Cocco, Jerome M Laurence, Emma S Johnston, Michael J Hollands, Henry C C Pleass, Arthur J Richardson, Vincent W T Lam.   

Abstract

BACKGROUND: Hepatic resection is a potentially curative therapy for hepatocellular carcinoma (HCC), but recurrence of disease is very common. Few studies have reported 10-year actual survival rates following hepatic resection; instead, most have used actuarial measures based on the Kaplan-Meier method. This systematic review aims to document 10-year actual survival rates and to identify factors significant in determining prognosis.
METHODS: A comprehensive search was undertaken of MEDLINE and EMBASE. Only studies reporting the absolute number of patients alive at 10 years after first resection for HCC were included; these figures were used to calculate the actual 10-year survival rate. A qualitative review and analysis of the prognostic factors identified in the included studies were performed.
RESULTS: Fourteen studies, all of which were retrospective case series, including data on 4197 patients with HCC were analysed. Ten years following resection, 303 of these patients were alive. The 10-year actual survival rate was 7.2%, whereas the actuarial survival quoted from the same studies was 26.8%. Positive prognostic factors included better hepatic function, a wider surgical margin and the absence of satellite lesions.
CONCLUSIONS: The actual long-term survival rate after resection of HCC is significantly inferior to reported actuarial survival rates. The Kaplan-Meier method of actuarial survival analysis tends to overestimate survival outcomes as a result of censorship of data and subgroup analysis.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22487065      PMCID: PMC3384847          DOI: 10.1111/j.1477-2574.2012.00446.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  21 in total

1.  Global cancer statistics.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

2.  A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

3.  Results of surgical resection for hepatocellular carcinoma.

Authors:  T K Choi; C S Edward; S T Fan; P T Francis; J Wong
Journal:  Hepatogastroenterology       Date:  1990-04

4.  Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy.

Authors:  Saburo Fukuda; Toshiyuki Itamoto; Hironobu Amano; Toshihiko Kohashi; Hideki Ohdan; Hirotaka Tashiro; Toshimasa Asahara
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

5.  Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma.

Authors:  C S Lee; J C Sheu; M Wang; H C Hsu
Journal:  Br J Surg       Date:  1996-03       Impact factor: 6.939

6.  Clinicopathologic features of patients with hepatocellular carcinoma surviving >10 years after hepatic resection.

Authors:  K Shirabe; M Shimada; K Kajiyama; T Gion; Y Ikeda; H Hasegawa; K Taguchi; K Takenaka; K Sugimachi
Journal:  Cancer       Date:  1998-12-01       Impact factor: 6.860

7.  Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years.

Authors:  N Nagasue; H Kohno; Y C Chang; H Taniura; A Yamanoi; M Uchida; T Kimoto; Y Takemoto; T Nakamura; H Yukaya
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

8.  Twenty-five-year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner.

Authors:  Joseph G Fortner; Yuman Fong
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

9.  Chinese experience with hepatectomy for huge hepatocellular carcinoma.

Authors:  X P Chen; F Z Qiu; Z D Wu; B X Zhang
Journal:  Br J Surg       Date:  2004-03       Impact factor: 6.939

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  46 in total

1.  Actual 10-year survival following hepatectomy for hepatocellular carcinoma.

Authors:  Bernardo Franssen; Ghalib Jibara; Parissa Tabrizian; Myron E Schwartz; Sasan Roayaie
Journal:  HPB (Oxford)       Date:  2013-12-24       Impact factor: 3.647

Review 2.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

3.  Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma.

Authors:  Jian Zheng; Deborah Kuk; Mithat Gönen; Vinod P Balachandran; T Peter Kingham; Peter J Allen; Michael I D'Angelica; William R Jarnagin; Ronald P DeMatteo
Journal:  Ann Surg Oncol       Date:  2016-12-05       Impact factor: 5.344

4.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

5.  Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.

Authors:  Ze-Xiao Lin; Dan-Yun Ruan; Yang Li; Dong-Hao Wu; Xiao-Kun Ma; Jie Chen; Zhan-Hong Chen; Xing Li; Tian-Tian Wang; Qu Lin; Jing-Yun Wen; Xiang-Yuan Wu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 6.  Review of preoperative transarterial chemoembolization for resectable hepatocellular carcinoma.

Authors:  Zhi-Hui Gao; Dou-Sheng Bai; Guo-Qing Jiang; Sheng-Jie Jin
Journal:  World J Hepatol       Date:  2015-01-27

7.  The prognostic value of homeobox B7 expression in patients with hepatocellular carcinoma.

Authors:  Yarong Guo; Xiaojiang Qin; Bao Chai; Junmei Jia; Jiahong Yi; Kang Wang; Xiaomin Hou
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

8.  Propofol inhibits hepatocellular carcinoma growth and invasion through the HMGA2-mediated Wnt/β-catenin pathway.

Authors:  Wei Ou; Jie Lv; Xiaohua Zou; Yin Yao; Jinli Wu; Jian Yang; Zhumei Wang; Yan Ma
Journal:  Exp Ther Med       Date:  2017-03-22       Impact factor: 2.447

9.  Tumor size is a major determinant of prognosis of resected stage I hepatocellular carcinoma.

Authors:  Wei-Ju Huang; Yung-Ming Jeng; Hong-Shiee Lai; Fang-Yu Bonnie Sheu; Po-Lin Lai; Ray-Hwang Yuan
Journal:  Langenbecks Arch Surg       Date:  2015-08-07       Impact factor: 3.445

Review 10.  Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma.

Authors:  Sebastian Mondaca; Hooman Yarmohammadi; Nancy E Kemeny
Journal:  Surg Oncol Clin N Am       Date:  2019-08-07       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.